Ignite Creation Date:
2024-05-05 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00792688
Status:
COMPLETED
Last Update Posted:
2021-10-28
First Post:
2008-11-14
Brief Title:
Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation
Sponsor:
TR Therapeutics
Organization:
TR Therapeutics
Study Overview
Official Title:
Double-Blind Randomized Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 01 and 10 Topically Applied GLYC-101 Compared to Placebo in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel GLYC-101 01 and GLYC-101 10 in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing CO2 LSR of the lower eyelids The study will observe the effects of the topical agent over the course of 1 month following the initial treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None